Table 1 Patients characteristics and demographics
All patients (n = 104) | Remission BVAS3 = 0 (n = 82) | Disease activity BVAS3 > 1 (n = 22) | |
|---|---|---|---|
Age, years, median (range) | 68 (20–86) | 68 (25–84) | 66 (20–86) |
Disease duration, years, median (range) | 7 (0–50) | 7 (0–50) | 1 (0–31) |
GPA, % (n) | 70 % (n = 73) | 68 % (n = 56) | 78 % (n = 18) |
MPA, % (n) | 22 % (n = 23) | 24 % (n = 19) | 17 % (n = 4) |
EGPA, % (n) | 8 % (n = 8) | 8 % (n = 7) | 4 % (n = 1) |
MPO-ANCA, % (n) | 30 % (n = 32) | 33 % (n = 26) | 26 % (n = 6) |
PR3-ANCA, % (n) | 59 % (n = 61) | 56 % (n = 46) | 70 % (n = 16) |
BVAS3, median (range) | 0 (0–16) | 0 | 4 (1–16) |
Leukocytes, 109/L, median (range)a | 6.4 (3.0–13.7) | 6 (3.2–13.7) | 7.9 (3.0–12) |
P-creatinine, μmol/L, median (range) | 98 (54–646) | 96 (59–635) | 143 (54–646) |
P-CRP, mg/L, median (range) | 2.6 (<0.6–92) | 2.6 (<0.6–27) | 5.7 (<0.6–92) |
Treatment b | |||
Prednisone, % (median dose of treated patients) | 60 % (6.25 mg) | 55 % (5 mg) | 77 % (15 mg) |
Azathioprine, % (n) | 28 % (n = 29) | 31 % (n = 26) | 13 % (n = 3) |
Mycophenolate mofetil, % (n) | 8 % (n = 8) | 10 % (n = 8) | 0 |
Rituximab, % (n) | 19 % (n = 20) | 19 % (n = 17) | 17 % (n = 3) |
Methotrexate, % (n) | 14 % (n = 15) | 14 % (n = 11) | 17 % (n = 4) |
Cyclophosphamide, % (n) | 11 % (n = 11) | 7 % (n = 6) | 27 % (n = 6) |